◆英語タイトル:PhaseRx Inc (PZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014046
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
PhaseRx Inc (PhaseRx), formerly PhaseRx Pharmaceuticals Inc is a healthcare products provider that conducts research and develops RNA nanomedicines for the treatment of orphan diseases. The company discovers and develops drugs based on SMARTT polymer technology, which offers mRNA delivery techniques. Its products under clinical development include PRX-OTC, PRX-ASL and argininosuccinatesynthetase. PhaseRx’s SMARTT polymer technology provides platform for the development of RNA-based drugs. The company offers products for the treatment of inherited metabolic disease and liver cancer. It has research collaborations with pharmaceutical and biotechnology companies. PhaseRx is headquartered in Seattle, Washington, the US.
PhaseRx Inc (PZRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PhaseRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PhaseRx Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PhaseRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PhaseRx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PhaseRx Inc, Medical Devices Deals, 2011 to YTD 2017 10
PhaseRx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PhaseRx Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
PhaseRx to Raise USD0.42 Million in Venture Financing 12
Phaserx Raises USD4 Million in Venture Financing 13
PhaseRx Raises US$1.4 Million In Venture Financing 14
PhaseRx Raises US$0.5 Million In Venture Financing 15
Phaserx Raises US$1.5 Million In Venture Financing 16
PhaseRx Raises US$1.6 Million In Venture Financing 17
Phaserx Raises US$3.6 Million In Venture Financing 18
Equity Offering 19
PhaseRx Plans to Raise up to USD15 Million in Public Offering of Shares and Warrants 19
Phaserx Raises USD18.5 Million in IPO 20
PhaseRx Raises Funds through Pivate Placement of Shares up on Exercise of Warrants 21
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 22
Debt Offering 23
PhaseRx Raises USD1.2 Million in Private Placement of Notes 23
PhaseRx Raises USD0.8 Million in Private Placement of Notes 24
Phaserx Raises USD1.54 Million in Private Placement of Notes 25
Phaserx Raises USD1.5 Million in Private Placement of Notes 26
PhaseRx Inc – Key Competitors 27
PhaseRx Inc – Key Employees 28
PhaseRx Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 09, 2017: PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update 30
Aug 10, 2017: PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update 31
May 12, 2017: PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update 32
Mar 27, 2017: PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 33
Nov 07, 2016: PhaseRx Reports Third Quarter 2016 Financial Results and Provides Corporate Update 34
Aug 02, 2016: PhaseRx Reports Second Quarter 2016 Financial Results and Provides Corporate Update 35
Corporate Communications 36
Aug 22, 2016: PhaseRx Appoints Peggy Phillips to Board of Directors 36
Feb 09, 2016: PhaseRx Strengthens Board of Directors and Leadership Team 37
Product News 38
Nov 08, 2016: PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology 38
06/21/2016: PhaseRx Announces Selection Of Lead Product Candidate PRX-OTC 39
02/08/2017: PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium 2017 40
Product Approvals 41
Nov 28, 2016: PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency 41
Clinical Trials 42
Jun 21, 2016: PhaseRx Announces Positive Proof-of-Concept Data for Product Candidate PRX-ASL 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Tables
PhaseRx Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PhaseRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PhaseRx Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PhaseRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PhaseRx Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PhaseRx Inc, Medical Devices Deals, 2011 to YTD 2017 10
PhaseRx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PhaseRx to Raise USD0.42 Million in Venture Financing 12
Phaserx Raises USD4 Million in Venture Financing 13
PhaseRx Raises US$1.4 Million In Venture Financing 14
PhaseRx Raises US$0.5 Million In Venture Financing 15
Phaserx Raises US$1.5 Million In Venture Financing 16
PhaseRx Raises US$1.6 Million In Venture Financing 17
Phaserx Raises US$3.6 Million In Venture Financing 18
PhaseRx Plans to Raise up to USD15 Million in Public Offering of Shares and Warrants 19
Phaserx Raises USD18.5 Million in IPO 20
PhaseRx Raises Funds through Pivate Placement of Shares up on Exercise of Warrants 21
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 22
PhaseRx Raises USD1.2 Million in Private Placement of Notes 23
PhaseRx Raises USD0.8 Million in Private Placement of Notes 24
Phaserx Raises USD1.54 Million in Private Placement of Notes 25
Phaserx Raises USD1.5 Million in Private Placement of Notes 26
PhaseRx Inc, Key Competitors 27
PhaseRx Inc, Key Employees 28
PhaseRx Inc, Subsidiaries 29